DURHAM, N.C. – A new, liquid means of treating scrapes and cuts will soon be on the way to market now that the U.S. Food and Drug Administration has approved “Nuvaderm” from

“This is great news,” a Chesson Labs spokesperson told Local Tech Wire.

The FDA granted market clearance for Nuvaderm after Chesson submitted it for approval in January. Since it is considered a medical device, clinical trials were not required, the Chesson spokesperson said.

"Nuvaderm’s clearance is a major milestone for Chesson Labs, but more importantly it is a product developed to improve wound care for individuals treating themselves as well as medical personnel who need a rapid response product to treat minor wounds," said Scott Neuville, Chesson’s chief executive officer.

Nuvaderm can be marketed and sold to healthcare professions and directly to consumers. It is "to cover intact skin and minor cuts, scrapes, burns or irritations of the skin, to help keep them clean and dry and help protect them from infection,” Chesson said. It does include antimicrobial properties.

Chesson also has plans to submit other products for approval.

Last year, Chesson geared up for its product launch with $3.3 million in new financing. The funding came shortly after Neuville’s hiring. He joined Chesson as part of a management reorganization in January 2008.

The company did not identify the investors in the Series A round.

Neuville replaced David Terry, who was CEO and a co-founder of the firm. He left Chesson in December 2007. Neuville recently left Qualyst, a developer of drug testing technology, as part of a management shakeup at that firm.

Chesson was formed in September 2006. It is working other products focused on dermatitis and nail fungus. The firm licensed for medical products a patented polymer developed by RMI Polymers.

Neuville is the former chairman of the board and CEO of iBiomatics, a SAS company. iBiomatics was the first healthcare technology spin-off of SAS Institute, the worlds largest privately held software company. Neuville had led Qualyst since 2002.

Terry formed the company along with Jerry Chesson, who discovered the technology on which Chesson Labs is based.